生物学的製剤による難病の治療革命

出版社: 日本医学出版
著者:
発行日: 2009-09-10
分野: 臨床医学:内科  >  膠原病/リウマチ
ISBN: 9784902266436
電子書籍版: 2009-09-10 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
発送目安:約3営業日

3,024 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,024 円(税込)

生物学的製剤による治療革命は、自己免疫疾患、悪性腫瘍、移植拒絶に留まらず、炎症性腸疾患、多発性硬化症などの神経疾患、天疱瘡、乾癬などの皮膚疾患、ベーチェット病眼病変、小児疾患などの多様な難病へも誘導され、各領域で治療のブレークスルーを引き起こす勢いである。本書では、生物学的製剤の領域の斯界の先生方にご執筆戴き、病態と治療の新しい考え方、新規治療導入の実際、今後の新展開に至るまでをまとめた。

目次

  • 表紙
  • 序文
  • 執筆者一覧
  • 目次
  • I. 関節リウマチ治療を一変させたTNF阻害療法
  • インフリキシマブの使用の実際と安全性
  • エタネルセプトの使用の実際と安全性
  • 完全ヒト型抗TNF抗体 (アダリムマブ, ゴリムマブ)
  • 抗IL-6R抗体 (トシリズマブ)
  • 寛解導入と治癒の可能性
  • 関節破壊進行の完全制御
  • 生命予後の改善
  • II. 期待される多様な分野への臨床応用
  • 炎症性腸疾患
  • 神経疾患 (多発性硬化症)
  • 血液・腫瘍疾患
  • 皮膚疾患
  • 眼疾患 (ベーチェット病)
  • 小児疾患
  • III. 現在申請中・開発中の生物学的製剤
  • CTLA4-Ig (アバタセプト)
  • 抗B細胞抗体
  • 抗B細胞表面分子療法 (ベリムマブ, アタシセプト)
  • 抗RANKL抗体製剤 (デノスマブ)
  • IV. イノベイティブ新薬開発促進の支援
  • PMDAの取り組み
  • 奥付

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 関節リウマチ治療を一変させたTNF阻害療法

P.7 掲載の参考文献
P.17 掲載の参考文献
3) Van Der Kooij SM, Van Der Bijl AE, Allaart CF, Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Gerards AH, et al : Remission Induction in Early Rheumatoid Arthritis (RA) with Initial Infliximab (IFX) and Methotrexate (MTX) Therapy : The Disease Course After IFX Discontinuation in The Best Trial. Arthritis Rheum ; 54 : S302, 2006
4) 日本リウマチ学会ホームページ : 関節リウマチ (RA) に対するTNF阻害療法施行ガイドライン (改訂版), http://www.ryumachi-jp.com/info/080201.html.
6) Vol.9, 全例調査の中間報告および死亡症例についてエ. ワイス株式会社, 武田薬品工業株式会社, 2008年12月
7) Harigai M : Efficacy and safety of etanercept in Japan : results from the postmarketing surveillance with 14,000 rheumatoid arthritis patients. Mod Rheumatol ; 18 : S9, 2008
8) Vol.8, ニューモシスチス肺炎および間質性肺炎についての検討結果 (抜粋). ワイス株式会社, 武田薬品工業株式会社, 2008年4月
P.24 掲載の参考文献
14) Furst D E M H Schiff, R M Fleischmann et al : Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis. results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30 : 2563-2571, 2003
15) Schiff M H, Burmester G R, Kent J D et al : Safety analyses of adalimumab (HUMIRA) in Efficacy and safety of adalimumab in patients with ankylosing spondylitis : results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54 : 2136-2146, 2006
P.34 掲載の参考文献
5) Nishimoto N, Yoshizaki Y, Maeda K et al : Toxicity, phamacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis : phase I/II clinical study. J Rheumatol 30 : 1426-1435, 2003
15) Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N : A case report of a patient with refractory adultonset Still's disease who was successfully treated with tocilizumab over 6 years (in press)
P.42 掲載の参考文献
P.52 掲載の参考文献
P.60 掲載の参考文献
1) Cobbs S, Anderson F, Bauer W : Length of life and cause of death in rheumatoid arthritis. N Engl J Med 249 (14) : 553-556, 1953
7) Pincus T, Callahan LF : Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity. J Rheumatol 13 (5) : 841-845, 1986
9) 宗圓聰 : RA患者の死亡率と死因. リウマチ科 37 (2) : 164-168, 2007
12) Wolfe F, Cathey MA : Analysis of methotrexate treatment effect in a longitudinal observational study : utility of cluster analysis. J Rheumatol 18 (5) : 672-727, 1991
15) Michaud K, Wolfe F : Reduced mortality among RA patients treated with anti-TNF therapy and methotrexate. Arthritis Rheum 52 : S145. 2005 (abstract)
16) Greenberg J, Lin SL, Decktor D et al : Association of duration of TNF antagonist treatment with reduction in cardiovascular outcomes in RA patients. Arthritis Rheum 54 : S422, 2006 (abstract)
19) Jacobsson LT, Turesson C, Giffe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P : Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (7) : 1213-1218, 2005
22) Hulimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Behir M, Spieker LE, Neidhart M, Michel BA, Gay RE, Lucher TF, Gay S, Ruschitzka F. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 22 ; 106 (17) : 2184-2187, 2002
24) Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF : Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32 (2) : 252-255, 2005

II. 期待される多様な分野への臨床応用

P.70 掲載の参考文献
1) Maini RN, Brennan FM, Williams R, Chu CQ, Cope AP, Gibbons D, Elliott M, Feldmann M : TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 11 (Suppl 8) : S173-175, 1993
2) van DuUemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J : Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 : 129-135, 1995
4) D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P : Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease : a European multicenter trial. Gastroenterology 116 : 1029-1034, 1999
11) Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T : Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 : 1145-1157, 2001
16) Youdlm A, Vasiliauskas EA, Targan Papadakis KA, Ippoliti A, Dubinsky Lechago J, Paavola J, Loane J, Lee Gaiennie J, Smith K, Do J, Abreu MT pilot study of adalimumab in in patients. Inflamm Bowel Dis 10 : 2004
24) Marzo-Ortega H, McGonagle D, O'Connor P, Emery P : Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 62 : 74-76, 2003
26) GoekooP-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) : arandomized, controlled trial. Arthritis Rheum 52 : 3381-3390, 2005
29) Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B : Infliximab as rescue therapy in severe to moderately severe ulcerative colitis : arandomized, placebo-controlled study. Gastroenterology 128 : 1805-1811, 2005
35) Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zakuciova M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T : Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55 : 1131-1137, 2006
36) Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre Jp, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T : A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 55 : 1138-1144, 2006
41) D'Haens G, Daperno M : Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 8 : 506-512, 2006
P.81 掲載の参考文献
2) StUe O, Marra CM, Jerome KR et al : Immune survemance in multipel sclerosis patients treated with natalizumab. Ann Neurol 59 : 743-747, 2006
4) Larger-Gould A, Atlas SW, Bollen AW et al : Progressive multifocal leukoencephalopathy in apatient treated with natalizumab. N Engl J Med 353 : 375-381, 2005
5) Kleinschmidt-DeMasters BK, Tyler KI : Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 : 369-374, 2005
8) Calabrest PA, Giovannoni G, Confavreux C et al : The incidence and significance of antinatalizumab antibodies. Results from AFFIRM and SENTINEL. Neurology 69 : 1391-1403, 2007
14) Bar-Or A, Calabresi P, Arnold DI et al : Rituximab in relapsing-remitting multiple sclerosis : a 72-week, open label, phase I trial. Annn Neurol 63 : 395-400, 2008
P.94 掲載の参考文献
1) ME Reff, K Carner, KS Chambers et al : Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 : 435-445, 1994
2) OW Press, J Howell-Clark, S Anderson et al : Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83 : 1390-1397, 1994
11) Knox SJ, Goris ML, Trisler K, Negrin R et al : Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2 (3) : 457-470, 1996
14) Grillo-Lopez AJ : Zevalin : the first radioim-munotherapy approved for the treatment of lymphomaExpert Rev Anticancer Ther 2 (5) : 485-493 (Review), 2002
21) 吉場史朗, 堀田知光, 飛内賢正ほか : 急性骨髄性白血病に対するCMA-676の有効性と安全性の評価-第II相試験の報告-. 臨床血液46 : 171 (733) [抄録], 2005
26) Kottaridis PD, Milligan DW, Chopra R et al : In vivo CAMPATH-1H prevents graft-versushost disease following nonmyeloablative stem cell transplantation. Blood 96 (7) : 2419-2425, 2000
29) Bonifazi F, Bandini G, Rondelli D et al : Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors : 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (10) : 2942-2947, 2001
37) Saltz L, Rubin M, Hochster H et al : Cetuximab (IMC-225) puls irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor. Proc ASCO 20 : 3a, 2001
P.101 掲載の参考文献
11) Salopek TG, Logsetty S, Tredget EE : Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, lifethreatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 47 : 785-788, 2002
P.106 掲載の参考文献
2) Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G : Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 31 : 1362-1368, 2004
3) 稲森由美子, 水木信久 : ベーチェット病の抗TNFα抗体療法. 眼科48 : 489-503, 2006
P.113 掲載の参考文献

III. 現在申請中・開発中の生物学的製剤

P.123 掲載の参考文献
5) LinksLinsley PS, Brady W, Urnes M et al : CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174 : 561-569, 1991
15) Genant HK, Peterfy CG, Westhovens R et al : Abatacept inhibits structural damage progression in rheumatoid arthritis : results from the long-term extension of the AIM trial. Ann Rheum Dis 2007 Dec 17 [Epub ahead of print]
P.129 掲載の参考文献
2) Dorner T, Brumester GR : New approaches of B-cell-directed therapy : beyond rituximab. Curr Opin Rheumatol 20 : 263-268, 2008
6) Keystone EC, Emery P, Peterfy CG et al : Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (in press)
P.138 掲載の参考文献
9) He B et al : Intestinal bacteria trigger T cell-independent immunoglobulin A (2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26 : 812-826, 2007
19) Zhang J et al : Cutting edge : a role for Blymphocyte stimulator in systemic lupus erythematosus, J Immunol 166 : 6-10, 2001
29) Cohen SB : Updates from B cell trials : efficacy. J Rheumatol 33 (Suppl 77) : 12-17, 2006
30) Dall' Era M et al : Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus : results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56 : 4142-4150, 2007
32) Dorner T, Burmester GR : No B cells-no active RA? Advances in B cell depletion in RA-repeated therapy under conditions of clinical practice. Rheumatology (Oxford) 46 : 563-564, 2007
P.145 掲載の参考文献

最近チェックした商品履歴

Loading...